Preparation and characterization of new challenge stocks of SIVmac32H J5 following rapid serial passage of virus in vivo

Background  A new challenge stock of the simian immunodeficiency virus SIVmacJ5 has been produced following passage in vivo.

[1]  D. O’Connor,et al.  Simian Immunodeficiency Virus SIVmac239 Infection of Major Histocompatibility Complex-Identical Cynomolgus Macaques from Mauritius , 2006, Journal of Virology.

[2]  J. Mascola,et al.  Pathogenicity of Simian-Human Immunodeficiency Virus SHIV-89.6P and SIVmac Is Attenuated in Cynomolgus Macaques and Associated with Early T-Lymphocyte Responses , 2005, Journal of Virology.

[3]  J. Heeney,et al.  Protective efficacy of a multicomponent vector vaccine in cynomolgus monkeys after intrarectal simian immunodeficiency virus challenge. , 2004, The Journal of general virology.

[4]  J. Margolick,et al.  Improved Coreceptor Usage Prediction and GenotypicMonitoring of R5-to-X4 Transition by Motif Analysis of HumanImmunodeficiency Virus Type 1 env V3 LoopSequences , 2003, Journal of Virology.

[5]  R. Doms,et al.  Mutations in the C3 region of human and simian immunodeficiency virus envelope have differential effects on viral infectivity, replication, and CD4-dependency. , 2003, Virology.

[6]  N. Almond,et al.  Simian immunodeficiency virus Nef gene regulates the production of 2-LTR circles in vivo. , 2003, Virology.

[7]  Gabriela Canziani,et al.  Rapid Progression to Simian AIDS Can Be Accompanied by Selection of CD4-Independent gp120 Variants with Impaired Ability To Bind CD4 , 2002, Journal of Virology.

[8]  John P. Moore,et al.  AIDS vaccine models: Challenging challenge viruses , 2002, Nature Medicine.

[9]  D. Hockley,et al.  In situ hybridization and immunolabelling study of the early replication of simian immunodeficiency virus (SIVmacJ5) in vivo. , 2001, The Journal of general virology.

[10]  A. Wade-Evans,et al.  Mechanisms of protection induced by live attenuated simian immunodeficiency virus , 2001, Journal of medical primatology.

[11]  Christopher J. Miller,et al.  Simian-Human Immunodeficiency Virus Containing a Human Immunodeficiency Virus Type 1 Subtype-E Envelope Gene: Persistent Infection, CD4+ T-Cell Depletion, and Mucosal Membrane Transmission in Macaques , 2000, Journal of Virology.

[12]  D. Ho,et al.  Enhanced Infectivity of an R5-Tropic Simian/Human Immunodeficiency Virus Carrying Human Immunodeficiency Virus Type 1 Subtype C Envelope after Serial Passages in Pig-Tailed Macaques (Macaca nemestrina) , 2000, Journal of Virology.

[13]  G. Hubbard,et al.  Cytokine Expression, Natural Killer Cell Activation, and Phenotypic Changes in Lymphoid Cells from Rhesus Macaques during Acute Infection with Pathogenic Simian Immunodeficiency Virus , 2000, Journal of Virology.

[14]  C. Arnold,et al.  Monoclonal antibodies recognize at least five epitopes on the SIV Nef protein and identify an in vitro-induced mutation. , 1999, AIDS research and human retroviruses.

[15]  H. Whittle,et al.  Low peripheral blood viral HIV-2 RNA in individuals with high CD4 percentage differentiates HIV-2 from HIV-1 infection. , 1998, Journal of human virology.

[16]  C. Cheng‐Mayer,et al.  Comparison of in vitro and in vivo infectivity of different clade B HIV-1 envelope chimeric simian/human immunodeficiency viruses in Macaca mulatta. , 1997, Virology.

[17]  J. Sodroski,et al.  A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys , 1996, Journal of virology.

[18]  H. McClure,et al.  Chimeric simian/human immunodeficiency virus that causes progressive loss of CD4+ T cells and AIDS in pig-tailed macaques , 1996, Journal of virology.

[19]  N. Almond,et al.  Assessing animal models of AIDS , 1995, Nature Medicine.

[20]  N. Almond,et al.  The development of PCR based assays for the detection and differentiation of simian immunodeficiency virus in vivo. , 1995, Journal of virological methods.

[21]  B. Clarke,et al.  Molecular and biological characterization of simian immunodeficiency virus macaque strain 32H proviral clones containing nef size variants. , 1994, The Journal of general virology.

[22]  R. Desrosiers,et al.  Titration and characterization of two rhesus-derived SIVmac challenge stocks. , 1994, AIDS research and human retroviruses.

[23]  H. Petry,et al.  Protection of monkeys by a split vaccine against SIVmac depends upon biological properties of the challenge virus , 1993, AIDS.

[24]  F. Taffs,et al.  Vaccine studies with the 32H reisolate of SIVmac251: an overview. , 1992, AIDS research and human retroviruses.

[25]  G. Schild,et al.  The quest for vaccines against AIDS: progress and challenges. An overview. , 1991, Vaccine.

[26]  L. Gritz,et al.  Production and of monoclonal antibodies to simian immunodeficiency virus envelope glycoproteins. , 1991, AIDS.

[27]  P. Greenaway,et al.  Preliminary report: protection of cynomolgus macaques against simian immunodeficiency virus by fixed infected-cell vaccine , 1990, The Lancet.

[28]  J. Denton.  Loctite UV 357 polymerised glass adhesive as a section mounting medium. , 1987, Journal of clinical pathology.

[29]  J. Devereux,et al.  A comprehensive set of sequence analysis programs for the VAX , 1984, Nucleic Acids Res..

[30]  G. Kärber,et al.  Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche , 1931, Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie.

[31]  J. Heeney,et al.  AIDS vaccine development in primate models. , 1998, AIDS.

[32]  J. Bonfield,et al.  A new DNA sequence assembly program. , 1995, Nucleic acids research.

[33]  A. Heath,et al.  Population sequence analysis of a simian immunodeficiency virus (32H reisolate of SIVmac251): a virus stock used for international vaccine studies. , 1992, AIDS research and human retroviruses.

[34]  K M Leighton,et al.  Modelling irrational numbers in analysis using elementary programming , 1992, The Mathematical Gazette.